UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

PloS one, 2014-08, Vol.9 (8), p.e105638

2014

Volltextzugriff (PDF)

CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial

BMJ open respiratory research, 2022-01, Vol.9 (1), p.e001060

2022

Volltextzugriff (PDF)

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

PloS one, 2014, Vol.9 (9), p.e110069

2014

Volltextzugriff (PDF)

Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients

Cancer chemotherapy and pharmacology, 2006-04, Vol.57 (4), p.401-411

2006

Volltextzugriff (PDF)

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion

Diabetes care, 2013-08, Vol.36 (8), p.2154-2161

2013

Volltextzugriff (PDF)

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study

Diabetes care, 2013-08, Vol.36 (8), p.2154-2161

2013

Volltextzugriff (PDF)

A semimechanistic-physiologic population pharmacokinetic/ pharmacodynamic model for neutropenia following pemetrexed therapy

Cancer chemotherapy and pharmacology, 2006-04, Vol.57 (4), p.412-426

2006

Volltextzugriff (PDF)

Assessment of CYP‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Journal of clinical pharmacology, 2024-08, Vol.64 (8), p.984-992

2024

Volltextzugriff (PDF)

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2019-04, Vol.21 (4), p.812-821

2019

Volltextzugriff (PDF)

Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus

The journal of clinical endocrinology and metabolism, 2013-05, Vol.98 (5), p.E867-E871

2013

Volltextzugriff (PDF)

Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy

Cancer chemotherapy and pharmacology, 2006-04, Vol.57 (4), p.427-435

2006

Volltextzugriff (PDF)

Outpatient versus inpatient mixed meal tolerance and arginine stimulation testing yields comparable measures of variability for assessment of beta cell function

Contemporary clinical trials communications, 2018-06, Vol.10, p.94-99

2018

Volltextzugriff (PDF)

Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects

Advances in therapy, 2020-12, Vol.37 (12), p.4944-4958

2020

Volltextzugriff (PDF)

Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study

Advances in therapy, 2020-10, Vol.37 (10), p.4381-4395

2020

Volltextzugriff (PDF)

Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis

Cardiovascular research, 2019-03, Vol.115 (3), p.669-677

2019

Volltextzugriff (PDF)

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects

Clinical pharmacology: advances and applications, 2023-01, Vol.15, p.9-19

2023

Volltextzugriff (PDF)

Arginine is preferred to glucagon for stimulation testing of β-cell function

American journal of physiology: endocrinology and metabolism, 2014-10, Vol.307 (8), p.E720-E727

2014

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants

Clinical pharmacology in drug development, 2022-12, Vol.11 (12), p.1394-1404

2022

Volltextzugriff (PDF)

Noninformative priors for one-parameter item response models

Journal of statistical planning and inference, 2000-07, Vol.88 (1), p.99-115

2000

Volltextzugriff (PDF)

Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction

European journal of heart failure, 2013-06, Vol.15 (6), p.679-689

2013

Volltextzugriff (PDF)

Arginine is preferred to glucagon for stimulation testing of [Beta]-cell function

American journal of physiology: endocrinology and metabolism, 2014-10, Vol.307 (8), p.E720

2014

Volltextzugriff (PDF)

Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans

International journal of clinical pharmacology and therapeutics, 2012-08, Vol.50 (8), p.584

2012

Volltextzugriff (PDF)

Divergent effects of raloxifene HCl on the the pharmacokinetics and pharmacodynamics of warfarin

Pharmaceutical research, 2001-07, Vol.18 (7), p.1024-1028

2001

Volltextzugriff (PDF)

HIERARCHICAL BAYESIAN ANALYSIS OF BINARY MATCHED PAIRS DATA

Statistica Sinica, 2000-04, Vol.10 (2), p.647-657

2000

Volltextzugriff (PDF)

Bayesian analysis of item response models for binary data

Ghosh, Atalanta

1996

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(26)
Dissertationen
(1)

Sprache

Englisch
(27)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study

A semimechanistic-physiologic population pharmacokinetic/ pharmacodynamic model for neutropenia following pemetrexed therapy

Assessment of CYP‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes

Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus

Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy

Outpatient versus inpatient mixed meal tolerance and arginine stimulation testing yields comparable measures of variability for assessment of beta cell function

Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects

Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study

Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects

Arginine is preferred to glucagon for stimulation testing of β-cell function

Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants

Noninformative priors for one-parameter item response models

Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction

Arginine is preferred to glucagon for stimulation testing of [Beta]-cell function

Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans

Divergent effects of raloxifene HCl on the the pharmacokinetics and pharmacodynamics of warfarin

HIERARCHICAL BAYESIAN ANALYSIS OF BINARY MATCHED PAIRS DATA

Bayesian analysis of item response models for binary data

Suchergebnisse filtern